GSA Capital Partners LLP Makes New Investment in STAAR Surgical Company $STAA

GSA Capital Partners LLP purchased a new position in STAAR Surgical Company (NASDAQ:STAA) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 39,390 shares of the medical instruments supplier’s stock, valued at approximately $910,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Amalgamated Bank boosted its holdings in STAAR Surgical by 3.6% in the 3rd quarter. Amalgamated Bank now owns 14,609 shares of the medical instruments supplier’s stock worth $393,000 after acquiring an additional 514 shares during the period. Invesco Ltd. boosted its holdings in STAAR Surgical by 0.6% in the 3rd quarter. Invesco Ltd. now owns 150,896 shares of the medical instruments supplier’s stock worth $4,055,000 after acquiring an additional 956 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in STAAR Surgical by 2,605.1% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 1,016 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in STAAR Surgical by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier’s stock worth $518,000 after acquiring an additional 1,267 shares during the period. Finally, CANADA LIFE ASSURANCE Co boosted its holdings in STAAR Surgical by 3.6% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 57,625 shares of the medical instruments supplier’s stock worth $1,546,000 after acquiring an additional 1,979 shares during the period. Hedge funds and other institutional investors own 96.70% of the company’s stock.

STAAR Surgical Stock Performance

STAAR Surgical stock opened at $32.47 on Friday. The stock has a market cap of $1.62 billion, a P/E ratio of -75.51 and a beta of 1.20. The company has a current ratio of 5.12, a quick ratio of 4.31 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average of $24.20 and a 200-day moving average of $22.86. STAAR Surgical Company has a 52 week low of $15.59 and a 52 week high of $35.87.

STAAR Surgical (NASDAQ:STAA) last released its earnings results on Wednesday, May 13th. The medical instruments supplier reported $0.10 EPS for the quarter, beating the consensus estimate of $0.05 by $0.05. The company had revenue of $93.52 million during the quarter, compared to analysts’ expectations of $78.72 million. STAAR Surgical had a positive return on equity of 3.31% and a negative net margin of 7.24%.The business’s revenue was up 119.6% on a year-over-year basis. During the same period in the prior year, the business posted ($1.10) EPS. On average, analysts expect that STAAR Surgical Company will post -0.03 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Wall Street Zen upgraded STAAR Surgical from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Mizuho upped their price target on STAAR Surgical from $22.00 to $27.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Wedbush upgraded STAAR Surgical from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $26.00 to $40.00 in a report on Thursday, May 14th. Canaccord Genuity Group upped their price target on STAAR Surgical from $27.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. Finally, Wells Fargo & Company increased their target price on STAAR Surgical from $16.00 to $25.00 and gave the company an “equal weight” rating in a research note on Friday, May 15th. Three analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $27.81.

Insider Activity at STAAR Surgical

In other STAAR Surgical news, Director Broadwood Partners, L.P. bought 316,017 shares of STAAR Surgical stock in a transaction dated Friday, March 13th. The stock was bought at an average cost of $18.61 per share, for a total transaction of $5,881,076.37. Following the purchase, the director owned 16,123,842 shares in the company, valued at $300,064,699.62. This represents a 2.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders purchased 670,213 shares of company stock worth $12,266,249. Corporate insiders own 39.90% of the company’s stock.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.